Rhj International S.A. (RHJIF) 4.5300 $RHJIF RHJ

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rhj International S.A. (RHJIF) 4.5300 $RHJIF

RHJ International: End of Share Buy-Back Programme
GlobeNewswire - Mon Feb 02, 10:45AM CST
RHJ International ("RHJI" announces that the share buy-back programme initiated on 31 October 2014 for the repurchase of up to 1.3 million shares for an aggregate consideration of up to EUR 6.5 million expired on 30 January 2015. RHJI hereby discloses information in accordance with Article 207 of the Royal Decree of 30 January 2001 in execution of the Belgian Company Code:

RHJ International: Update on Share Buy-Back Program 2014
GlobeNewswire - Mon Jan 26, 9:48AM CST
RHJ International ("RHJI" hereby discloses information in accordance with Article 207 of the Royal Decree of 30 January 2001 in execution of the Belgian Company Code:

RHJ International: Notice to Shareholders of Extraordinary Shareholders' Meeting
GlobeNewswire - Fri Jan 23, 2:33AM CST
RHJ International SA ("RHJI" hereby provides notice to shareholders of the Extraordinary Shareholders' Meeting, to be held on 24 February 2015, at 3 p.m. CET, at Avenue Louise 326, 1050 Brussels (Belgium).

RHJ International Announces Sale of Interest in Ripplewood Advisors LLC
GlobeNewswire - Mon Jan 05, 1:07AM CST
RHJ International ("RHJI" is announcing today that it has completed the sale of its interest in Ripplewood Advisors LLC ("Ripplewood Advisors" to an affiliate of Timothy C. Collins. Ripplewood Advisors was previously known as Kleinwort Benson Advisors LLC. The license of the name Kleinwort Benson Advisors has also been terminated.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Insights from the New First Presidency on Global Challenges

Updated Category News Views 218

A Historic Conversation with the First Presidency The recent interview featuring the new First Presidency of The Church of Jesus Christ of Latter-day Saints marks an exciting milestone. Conducted by the talented Jane Clayson Johnson, this unique dialogue sheds light on pressing issues within the Church and broader society. It was their first public discussion, making it a...

Continue Reading
Major Bets on Donald Trump's Election Surge Past $52 Million

Updated Category News Views 119

Significant Bets on Trump's Electoral Success A trader on Polymarket, operating under the alias Fredi9999, alongside four other accounts, has made headlines recently by placing enormous bets on Donald Trump’s electoral prospects. This activity has generated considerable chatter among traders in the market. Tracking Trump's Betting Activity Harry Crane, a statistics...

Continue Reading
FMC Corporation Faces Lawsuit Over Securities Violations

Updated Category News Views 190

FMC Corporation Faces Lawsuit Over Securities Violations Recently, the Gross Law Firm has alerted shareholders of FMC Corporation (NYSE: FMC) regarding significant legal developments. This lawsuit brings attention to serious allegations concerning the company's conduct during a specific class period. Shareholder Engagement and Participation Shareholders who purchased FMC...

Continue Reading
Insider Buying at Optima Health Signals Confidence in Future Growth

Updated Category News Views 132

Insightful Insider Share Purchase at Optima Health Optima Health plc (AIM: OPT), a leading provider of corporate health and wellbeing solutions in the UK, recently announced an important transaction involving one of its key insiders. Joanne Newey, who takes on the role of Group Business Development & Propositions Director and is also a Person Discharging Managerial...

Continue Reading
Outlook Therapeutics Prepares for Upcoming Investor Interaction

Updated Category News Views 78

Outlook Therapeutics Connects with Investors at Upcoming Virtual Event ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related...

Continue Reading